Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T11:51:01.518Z.
Calculation as of: 2026-10-06T11:51:01.518Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: aa9bc7f9cefff507f8a4fe626b62717351a0ace1a98d881cea9fd3b4864bb5d1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Clover Health Investments, Corp.
Market Cap
$2.43B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.51B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.17B
EBITDA Yield
N/A
TTM Avg
1.31%
3Y Avg
2.16%
5Y Avg
2.16%
Market Cap
$2.69B
EBITDA Yield
10.53%
TTM Avg
12.59%
3Y Avg
12.00%
5Y Avg
11.83%
Market Cap
$2.69B
EBITDA Yield
7.55%
TTM Avg
8.87%
3Y Avg
7.02%
5Y Avg
6.94%
Market Cap
$2.11B
EBITDA Yield
7.79%
TTM Avg
7.38%
3Y Avg
6.36%
5Y Avg
5.86%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clover Health Investments, Corp. (CLOV) | $2.43B | N/A | N/A | N/A | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.34B | 9.37% | 7.20% | 4.06% | 4.06% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.51B | N/A | N/A | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.64B | N/A | N/A | N/A | N/A |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.64B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.17B | N/A | 1.31% | 2.16% | 2.16% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | 10.53% | 12.59% | 12.00% | 11.83% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 7.55% | 8.87% | 7.02% | 6.94% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 7.79% | 7.38% | 6.36% | 5.86% |
| Alvotech (ALVO)vs › | $2.07B | 2.39% | 3.21% | 2.55% | 2.55% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
